Pfizer Inc. $PFE Shares Purchased by Swedbank AB

Swedbank AB raised its position in Pfizer Inc. (NYSE:PFE) by 12.0% in the 1st quarter, Holdings Channel reports. The fund owned 6,150,865 shares of the biopharmaceutical company’s stock after purchasing an additional 660,593 shares during the period. Swedbank AB’s holdings in Pfizer were worth $172,716,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Vermillion Wealth Management Inc. boosted its position in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 382 shares during the last quarter. Triad Wealth Partners LLC increased its position in shares of Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 386 shares during the last quarter. Eagle Capital Management LLC lifted its stake in shares of Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after acquiring an additional 390 shares in the last quarter. ETF Store Inc. boosted its stake in shares of Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares during the last quarter. Finally, Mattern Wealth Management LLC grew its position in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.39 during midday trading on Tuesday, hitting $24.11. 15,358,688 shares of the company’s stock were exchanged, compared to its average volume of 42,630,352. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The firm has a market cap of $137.43 billion, a P/E ratio of 18.41 and a beta of 0.35. The stock’s 50 day moving average price is $25.63 and its 200-day moving average price is $26.23. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the previous year, the firm posted $0.92 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won FDA approval for a new IBRANCE use in HR-positive, HER2-positive metastatic breast cancer, adding a fresh clinical and commercial catalyst that could support future sales. Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
• Positive Sentiment: Several articles highlighted Pfizer as a “dirt cheap” healthcare stock, suggesting value investors may see upside if the company can stabilize growth and capitalize on its cash-generating franchise. Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
• Positive Sentiment: Cantor Fitzgerald reiterated a neutral rating with a $27 price target, implying meaningful upside from recent trading levels and showing Wall Street still sees room for recovery. Benzinga rating note
• Neutral Sentiment: Pfizer Limited announced its annual meeting and proposed a final dividend, but this appears related to a different Pfizer entity and is unlikely to affect Pfizer Inc. shares. Pfizer Limited Sets July 28 Virtual AGM, Proposes Rs 75 Final Dividend
• Neutral Sentiment: Comparisons with AstraZeneca and Alnylam mostly reinforce the view that Pfizer faces stronger near-term growth questions than some peers, but these pieces are more comparative than company-specific. Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
• Negative Sentiment: Analysts downgraded Pfizer to Hold, citing delayed pipeline catalysts, management changes, and weaker near-term rerating potential, which likely weighed on the stock. Pfizer’s Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
• Negative Sentiment: Pfizer was also described as sinking while the broader market advanced, reflecting continued investor concern about its growth outlook and keeping pressure on shares. Pfizer (PFE) Stock Sinks As Market Gains: Here’s Why

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PFE. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. UBS Group reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Tuesday, June 23rd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Monday. Finally, Wolfe Research reissued an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.59.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.